Why Is Vir Biotechnology Stock Falling Friday?
Source: Benzinga ·
Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10 per share, raising concerns about shareholder dilution. $150 Million Equity Offering Vir Biotechnolo
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.